These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 14757427

  • 61. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis.
    Wallace DF, Clark RM, Harley HA, Subramaniam VN.
    J Hepatol; 2004 Apr; 40(4):710-3. PubMed ID: 15030991
    [Abstract] [Full Text] [Related]

  • 62. SLC40A1-R178G or R178Q and ferroportin disease? A call for vigilance in mutation reporting.
    Wallace DF.
    J Hepatol; 2013 Aug; 59(2):396-7. PubMed ID: 23523714
    [No Abstract] [Full Text] [Related]

  • 63. Flatiron mice and ferroportin disease.
    Johnson EE, Wessling-Resnick M.
    Nutr Rev; 2007 Jul; 65(7):341-5. PubMed ID: 17695375
    [Abstract] [Full Text] [Related]

  • 64. HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening.
    Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, McLaren GD, Eckfeldt JH, McLaren CE, Reboussin DM, Gordeuk VR, Speechley MR, Reiss JA, Press RD, Dawkins FW, Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators.
    Genet Test; 2007 Jul; 11(3):269-75. PubMed ID: 17949288
    [Abstract] [Full Text] [Related]

  • 65. Genetic haemochromatosis: genes and mutations associated with iron loading.
    Camaschella C, Roetto A, De Gobbi M.
    Best Pract Res Clin Haematol; 2002 Jun; 15(2):261-76. PubMed ID: 12401307
    [Abstract] [Full Text] [Related]

  • 66. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls.
    Holmström P, Marmur J, Eggertsen G, Gåfvels M, Stål P.
    Gut; 2002 Nov; 51(5):723-30. PubMed ID: 12377814
    [Abstract] [Full Text] [Related]

  • 67. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features.
    Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E.
    Blood Cells Mol Dis; 2005 Nov; 34(2):157-61. PubMed ID: 15727899
    [Abstract] [Full Text] [Related]

  • 68. Reply to: "SLC40A1-R178G or R178Q and ferroportin disease? A call for vigilance in mutation reporting".
    Speletas M, Kioumi A, Germenis AE.
    J Hepatol; 2013 Aug; 59(2):397. PubMed ID: 23523713
    [No Abstract] [Full Text] [Related]

  • 69. Genetic and clinical heterogeneity of ferroportin disease.
    Cremonesi L, Forni GL, Soriani N, Lamagna M, Fermo I, Daraio F, Galli A, Pietra D, Malcovati L, Ferrari M, Camaschella C, Cazzola M.
    Br J Haematol; 2005 Dec; 131(5):663-70. PubMed ID: 16351644
    [Abstract] [Full Text] [Related]

  • 70. Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload.
    Altamura S, Kessler R, Gröne HJ, Gretz N, Hentze MW, Galy B, Muckenthaler MU.
    Cell Metab; 2014 Aug 05; 20(2):359-67. PubMed ID: 25100063
    [Abstract] [Full Text] [Related]

  • 71. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.
    Kawabata H.
    Int J Hematol; 2018 Jan 05; 107(1):31-43. PubMed ID: 29134618
    [Abstract] [Full Text] [Related]

  • 72. Ferroportin disease: A novel SLC40A1 mutation.
    Ravasi G, Pelucchi S, Russo A, Mariani R, Piperno A.
    Dig Liver Dis; 2020 Jun 05; 52(6):688-690. PubMed ID: 32360131
    [No Abstract] [Full Text] [Related]

  • 73. Microelements and inherited metabolic diseases.
    Marklová E.
    Acta Medica (Hradec Kralove); 2002 Jun 05; 45(4):129-33. PubMed ID: 12587779
    [Abstract] [Full Text] [Related]

  • 74. [Diagnosis of 5 patients with possible primary hemochromatosis].
    Jacobs EM, de Vries RA, Elving LD, Stalenhoef AF, Swinkels DW.
    Ned Tijdschr Geneeskd; 2003 Apr 05; 147(14):666-70. PubMed ID: 12712652
    [Abstract] [Full Text] [Related]

  • 75. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
    Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, Bastin JM, Cowley D, Chinthammitr Y, Robson KJ, Townsend AR.
    Blood; 2005 May 15; 105(10):4096-102. PubMed ID: 15692071
    [Abstract] [Full Text] [Related]

  • 76. Diagnosing aceruloplasminemia: navigating through red herrings.
    Kharel Z, Kharel H, Phatak PD.
    Ann Hematol; 2024 Jun 15; 103(6):2173-2176. PubMed ID: 38637332
    [Abstract] [Full Text] [Related]

  • 77. Disruption of the Hepcidin/Ferroportin Regulatory System Causes Pulmonary Iron Overload and Restrictive Lung Disease.
    Neves J, Leitz D, Kraut S, Brandenberger C, Agrawal R, Weissmann N, Mühlfeld C, Mall MA, Altamura S, Muckenthaler MU.
    EBioMedicine; 2017 Jun 15; 20():230-239. PubMed ID: 28499927
    [Abstract] [Full Text] [Related]

  • 78. [Management of hyperferritinemia].
    Delwaide J, Giet D, Lamproye A, Belaïche J.
    Rev Med Liege; 2006 Jun 15; 61(5-6):329-33. PubMed ID: 16910257
    [Abstract] [Full Text] [Related]

  • 79. [Biology and genetics of iron metabolism abnormalities. 7th Joint Meeting Inserm-SFBC. Paris, 27 November 1997].
    Brissot P.
    Ann Biol Clin (Paris); 1998 Jul 15; 56 Spec No():4. PubMed ID: 9867723
    [No Abstract] [Full Text] [Related]

  • 80. Epidemiology and diagnostic testing for hemochromatosis and iron overload.
    Adams PC.
    Int J Lab Hematol; 2015 May 15; 37 Suppl 1():25-30. PubMed ID: 25976957
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.